Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

(EXMWW)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00600.0000 (0.00%)
At close: 11:11AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0060
Open0.0060
BidN/A x N/A
AskN/A x N/A
Day's Range0.0060 - 0.0060
52 Week Range0.0060 - 0.0060
Volume825
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Life Sciences Investor Forum Presentations Now Available for On-Demand Viewing

    NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23rd Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOGIN AT: https://bit.ly/3nbZJuOThe company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section. Companies are accepting 1x1 manag

  • GlobeNewswire

    UPDATE - Life Sciences Investor Forum: Company Executives Present Live June 23rd

    Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23rd. Individual investors, institutional investors, advisors, and analysts are invited to attend. The program begins at 9:30 AM EDT on Thursday,

  • PR Newswire

    Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update

    Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported financial results for the three months ended March 31, 2022 and provided a business update.

Advertisement
Advertisement